» Articles » PMID: 24216478

Peptidases Released by Necrotic Cells Control CD8+ T Cell Cross-priming

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2013 Nov 13
PMID 24216478
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Cross-priming of CD8+ T cells and generation of effector immune responses is pivotal for tumor immunity as well as for successful anticancer vaccination and therapy. Dead and dying cells produce signals that can influence Ag processing and presentation; however, there is conflicting evidence regarding the immunogenicity of necrotic cell death. We used a mouse model of sterile necrosis, in which mice were injected with sterile primary necrotic cells, to investigate a role of these cells in priming of CD8+ T cells. We discovered a molecular mechanism operating in Ag donor cells that regulates cross-priming of CD8+ T cells during primary sterile necrosis and thereby controls adaptive immune responses. We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase 1 (TOP-1), both of which are present in nonimmunogenic necrotic cells, eliminated proteasomal degradation products and blocked Ag cross-presentation. While sterile necrotic tumor cells failed to induce CD8+ T cell responses, their nonimmunogenicity could be reversed in vitro and in vivo by inactivation of DPP-3 and TOP-1. These results indicate that control of cross-priming and thereby immunogenicity of primary sterile necrosis relies on proteasome-dependent oligopeptide generation and functional status of peptidases in Ag donor cells.

Citing Articles

DPP3 expression promotes cell proliferation and migration and tumour growth , which is associated with poor prognosis of oesophageal carcinoma.

Liu J, Abudula A, Yang H, Xu L, Nuerrula Y, Bai G Oncol Rep. 2022; 49(1).

PMID: 36382663 PMC: 9685367. DOI: 10.3892/or.2022.8446.


DPP3: From biomarker to therapeutic target of cardiovascular diseases.

Ye P, Duan W, Leng Y, Wang Y, Tan X, Wang W Front Cardiovasc Med. 2022; 9:974035.

PMID: 36312232 PMC: 9605584. DOI: 10.3389/fcvm.2022.974035.


Survey of Dipeptidyl Peptidase III Inhibitors: From Small Molecules of Microbial or Synthetic Origin to Aprotinin.

Abramic M, Agic D Molecules. 2022; 27(9).

PMID: 35566358 PMC: 9101112. DOI: 10.3390/molecules27093006.


Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.

Birmpilis A, Paschalis A, Mourkakis A, Christodoulou P, Kostopoulos I, Antimissari E Cells. 2022; 11(9).

PMID: 35563721 PMC: 9102069. DOI: 10.3390/cells11091415.


Interdisciplinary Study of the Effects of Dipeptidyl-Peptidase III Cancer Mutations on the KEAP1-NRF2 Signaling Pathway.

Matic S, Tomasic Paic A, Sobocanec S, Pinteric M, Pipalovic G, Martincic M Int J Mol Sci. 2022; 23(4).

PMID: 35216111 PMC: 8878202. DOI: 10.3390/ijms23041994.


References
1.
Lev A, Takeda K, Zanker D, Maynard J, Dimberu P, Waffarn E . The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. Immunity. 2008; 28(6):787-98. PMC: 2587262. DOI: 10.1016/j.immuni.2008.04.015. View

2.
Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

3.
Shen L, Sigal L, Boes M, Rock K . Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity. 2004; 21(2):155-65. DOI: 10.1016/j.immuni.2004.07.004. View

4.
Li Y, Wang L, Pang P, Cui Z, Aung S, Haley D . Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res. 2011; 17(22):7047-57. PMC: 3495614. DOI: 10.1158/1078-0432.CCR-11-0951. View

5.
Lin M, Zhan Y, Villadangos J, Lew A . The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol. 2008; 86(4):353-62. DOI: 10.1038/icb.2008.3. View